{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:18:52Z","timestamp":1789611532982,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jiac.2022.10.010","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:01:17Z","timestamp":1666702877000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan"],"prefix":"10.1016","volume":"29","author":[{"given":"Shigeru","family":"Kohno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-5386","authenticated-orcid":false,"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0962-5758","authenticated-orcid":false,"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6067-9049","authenticated-orcid":false,"given":"Katsuhiko","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tateda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-5706","authenticated-orcid":false,"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-0869","authenticated-orcid":false,"given":"Yoshitsugu","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumito","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6251-1696","authenticated-orcid":false,"given":"Hiroshi","family":"Kakeya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-3660","authenticated-orcid":false,"given":"Junko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8526","authenticated-orcid":false,"given":"Shun-ichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsukazu","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Niki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2022.10.010_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01062-2016","article-title":"Predictors of mortality in chronic pulmonary aspergillosis","volume":"49","author":"Lowes","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiac.2022.10.010_bib2","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2022.10.010_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0091270010395510","article-title":"Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers","volume":"52","author":"Lee","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2022.10.010_bib4","series-title":"Revised guidelines for therapeutic drug monitoring of antimicrobials","year":"2016"},{"key":"10.1016\/j.jiac.2022.10.010_bib5","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.010_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2022.10.010_bib9","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiac.2022.10.010_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2022.10.010_bib11","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.010_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.jiac.2022.10.010_bib13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2022.10.010_bib14","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of medical Mycology in cooperation with the mycoses study group education and research consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.010_bib15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.010_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249455","article-title":"Prognostic factors of chronic pulmonary aspergillosis: a retrospective cohort of 264 patients from Japan","volume":"16","author":"Kimura","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2022.10.010_bib17","series-title":"Guidelines for the diagnosis and management of deep-seated mycosis preparation committee. Japanese Domestic Guidelines for the Management of deep-seated mycosis 2014","year":"2014"},{"key":"10.1016\/j.jiac.2022.10.010_bib18","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.3314\/mmj.16-00010","article-title":"Executive summary of Japanese Domestic guidelines for management of deep-seated mycosis 2014","volume":"57","author":"Kohno","year":"2016","journal-title":"Med Mycol J"},{"key":"10.1016\/j.jiac.2022.10.010_bib19","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.010_bib20","series-title":"Medical important fungi: a guide to identification","author":"Yamaguchi","year":"2013"},{"key":"10.1016\/j.jiac.2022.10.010_bib21","article-title":"Reference method for Broth Dilution antifungal susceptibility testing of yeasts","year":"2017"},{"key":"10.1016\/j.jiac.2022.10.010_bib22","series-title":"Reference method for Broth Dilution antifungal susceptibility testing of filamentous fungi. Approved standard","year":"2017"},{"key":"10.1016\/j.jiac.2022.10.010_bib23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.010_bib24","first-page":"63","article-title":"[Clinical study of fluconazole on deep-seated fungal infections]","volume":"42","author":"Ikemoto","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2022.10.010_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety","volume":"51","author":"Hamill","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.010_bib26","first-page":"1","article-title":"[A randomized, active controlled, open-label, comparative study to assess the safety and efficacy of posaconazole in Japanese subjects with deep-seated fungal infection]","volume":"61","author":"Kohno","year":"2020","journal-title":"Med Mycol J"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22002938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22002938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:05:33Z","timestamp":1761159933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22002938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1341321X22002938"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.010","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}